Home > Resources > Whitepapers > A Cure for Pharmaceutical Supply Chain Complexity

A Cure for Pharmaceutical Supply Chain Complexity

The pharmaceutical industry lags in the sophistication and performance of its supply chains when they are compared with best-in-class companies in other industries. This is due to the complexity that has come with new drugs, more complex production technologies and evolving regulatory requirements. In this environment, integrating and aligning the supply chain makes it more flexible, bolstering operational performance and financial competitiveness. The complexity of drug product supply chains has increased in recent years thanks mainly to the development of more complex chemical molecules (with more synthesis steps), more suppliers and geographies in the chain, and reduced average production volumes. Preparing for commercial release, the time from raw material to finished drug product can be as long as two years, and those months are fraught with hazards that can cause delays and rework, leading to extra costs, stock-outs and poor capacity utilization.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

DDD Group Limited

DDD Limited comprises a group of companies which between them offer a complete service to take a health and beauty product from idea to a consumer’s shopping basket. At DDD, we have been making and selling health and beauty products for almost 100 years, and all the skills we have gained in that time are available to you. Our operating companies are run as separate business units, but can all work together to deliver a range of services to our partners. All of our businesses operate with our core purpose at the forefront of how we work: Helping people be at their best in a way we can be proud of.

OTHER WHITEPAPERS
news image

Overcoming The Challenges of Pediatric Formulation

whitePaper | February 15, 2023

Pediatric populations represent the most diverse patient groups in all of medicine. Factors such as individual preferences, physiology, and dosage considerations all serve to complicate drug formulation aimed at pediatric care.

Read More
news image

Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

whitePaper | January 15, 2023

Oncology breakthroughs are currently fueling significant growth in the market, as well as the competition between pharmaceutical brands for market share. As increasingly individualized cancer treatments become available,

Read More
news image

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

Read More
news image

Simulation in the pharmaceutical industry

whitePaper | November 24, 2022

The pharmaceutical industry will face many challenges over the next decade, from industry-wide trends to new operational pressures. The key to meeting these challenges is adopting an agile, scalable and efficient approach to drug discovery and manufacturing.

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

Blockchain technology in the pharmaceutical industry

whitePaper | March 11, 2022

Blockchain technology is accelerating digital transformation across multiple industries, including the pharmaceutical industry.

Read More

Overcoming The Challenges of Pediatric Formulation

whitePaper | February 15, 2023

Pediatric populations represent the most diverse patient groups in all of medicine. Factors such as individual preferences, physiology, and dosage considerations all serve to complicate drug formulation aimed at pediatric care.

Read More

Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

whitePaper | January 15, 2023

Oncology breakthroughs are currently fueling significant growth in the market, as well as the competition between pharmaceutical brands for market share. As increasingly individualized cancer treatments become available,

Read More

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

Read More

Simulation in the pharmaceutical industry

whitePaper | November 24, 2022

The pharmaceutical industry will face many challenges over the next decade, from industry-wide trends to new operational pressures. The key to meeting these challenges is adopting an agile, scalable and efficient approach to drug discovery and manufacturing.

Read More

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More

Blockchain technology in the pharmaceutical industry

whitePaper | March 11, 2022

Blockchain technology is accelerating digital transformation across multiple industries, including the pharmaceutical industry.

Read More
More Whitepapers

Spotlight

DDD Group Limited

DDD Limited comprises a group of companies which between them offer a complete service to take a health and beauty product from idea to a consumer’s shopping basket. At DDD, we have been making and selling health and beauty products for almost 100 years, and all the skills we have gained in that time are available to you. Our operating companies are run as separate business units, but can all work together to deliver a range of services to our partners. All of our businesses operate with our core purpose at the forefront of how we work: Helping people be at their best in a way we can be proud of.

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference